AdvertiseDonate
PortlandSeattleDallasJacksonvilleColumbusWashingtonBostonDetroit
Friday, November 20, 2026Fresh headlines, all day.
Digital News Live · 70 SW Century Drive, Bend, OR 97702
News · Miami-Dade

Blood test detects CTE in 18 of 21 former football players

Researchers identified a specific protein, eMTBR-tau, that distinguishes between stages of chronic traumatic encephalopathy, moving the diagnosis from postmortem analysis toward in-life screening.

By Alessia Desai ·

Illustration for: Blood test detects CTE in 18 of 21 former football players
Illustration generated for this article, not a news photograph.

A new study published in the Journal of the American Medical Association on November 19 identifies a blood protein capable of detecting chronic traumatic encephalopathy, or CTE. The research team, led by Boston University and Banner Health, found that levels of a protein called endogenously cleaved microtubule-binding region tau, or eMTBR-tau, varied according to the severity of the disease in former athletes.

The study examined 21 former football players who donated their brains to the Boston University CTE Center after death. Autopsies confirmed that 18 of these men had CTE, while three did not. Of the 18 with the disease, 16 presented with high-stage CTE, the most severe form associated with significant memory and behavioral changes. The remaining two had lower stages of the condition.

Concentrations of eMTBR-tau were markedly higher in the blood samples of participants with high-stage CTE compared to those with low-stage CTE or no CTE. This protein serves as a biomarker for the tau tangles that characterize the disease, which are also present in Alzheimer’s. The findings suggest that a simple blood draw could distinguish between the stages of CTE, a capability that currently requires an autopsy.

Michael Alosco, a co-senior author and co-director of clinical research at the Boston University CTE Center, described the discovery as a potential turning point for diagnosis. “It’s a game-changer,” Alosco said. “Because if this study holds up with future research, if we validate it, then you’re talking about a biomarker that can help us to detect it during life.” He noted that the team is currently in the discovery phase and that further work is required to validate the test.

The cohort included players from various levels of competition. Twelve of the participants had played professionally, seven played in college, and two played in high school. Eleven of the professional players had high-stage CTE, as did four of the seven college players and one of the two high school players. The median age at death for participants with CTE was 73, while the median age for those without the disease was 51.

One participant was Ron “Bogie” Edwards, a former athlete from Utah State University who also played in the Canadian and Continental Football Leagues. Edwards died last year at age 79. His son, Rogue Edwards, said his father had suffered from forgetfulness and disorientation in his final years. An autopsy revealed advanced CTE. “I am so excited that my dad’s final contribution to the world can potentially help millions,” Rogue Edwards said.

The ability to detect CTE in living patients would allow researchers to enroll specific individuals in clinical trials for potential treatments. Doctors would be able to monitor drug effectiveness and identify patients with the condition before severe symptoms emerge. The blood test would work alongside other diagnostic methods to confirm a diagnosis.

CTE is a progressive neurodegenerative disease linked to repeated head impacts. It has no known cure and is associated with memory loss, impaired judgment, and behavioral changes. Previous research has sought to determine how prevalent the disease is among former NFL players. A study published in August 2026 found that at least one in four players who died between 2016 and 2021 had CTE. A subsequent study in October 2026 estimated that three out of four players who died between 2008 and 2023 likely had the disease.

Alosco stated that larger studies are necessary to confirm the accuracy of the eMTBR-tau findings. Additional research will also be needed to determine effective treatments for the condition. The current study relied on blood samples drawn while the players were alive and brain tissue collected after their deaths between 2008 and October 2026.

More News · Report a business · Got a Story?

Get Digital News Live in your inboxFresh headlines, all day. Free, a few times a week, unsubscribe any time.

Related stories

Get Digital News Live in your inboxFresh headlines, all day. Free, a few times a week, unsubscribe any time.